Journal article Open Access
Sunil T.Galatage1*, S.G.Killedar2, Anil Patil3, Swapnil Harale4, Y. R. Hundekar4
Objective: Rizatriptan Benzoate is the 5H1 receptor agonist and used in treatment of migraine, cluster headache. The main objective is to develop ideal anti-migraine nasal mucoadhesive microparticles as local and systemic drug delivery system. Method: An attempt was made to formulate the nasal mucoadhesive microparticle of Rizatriptan Benzoate with excipients like mucoadhesive polymers i.e HPMC, ethyl cellulose etc., by using modified solvent evaporation method. And evaluated them for production yield, drug loading efficiency, surface morphology by SEM, drug content, particle size, In-vitro drug release studies. The release rates were studied using GRAPHPAD PRISM software. Result and discussion: The prepared microparticles of Rizatriptan Benzoateformulations were found to be satisfactory particle size i.e in the range of 36.96 to 53.28µm,mucoadhesion time of F5 found to be 370 min,drug content was found to be72.86 % to 81.80 % and drug release of the drug follow zero order kinetic model. Optimized formulation F5shows that the developed formulations have shown improved dissolution profile in comparison to other formulation.The developed nasal mucoadhesive microparticles are having potential to deliver of anti-migraine drugs via nasal route.